Tagged with R

Mexico Founded in 1943, Mexican drugmaker Silanes has built a strong presence across multiple therapeutic areas, namely diabetes and cardiovascular, while expanding into others. The company’s director of pharma and biologics, Rafael Quintanilla, explains Silanes’ journey from being purely a branded generics manufacturer to embracing R&D, which has brought substantial growth…

Global Contract research organisations (CROs) have proven to be increasingly vital partners for the global biopharmaceutical industry guaranteeing efficient and compliant clinical trials that help to advance their candidates towards regulatory approvals. CROs have also demonstrated their ability to adapt to the industry’s changing needs by enlarging their geographical reach and…

China A roundup of some of the biggest China pharma industry stories, including the progress of the US Biosecure Act targeting Chinese biotechs; Innovent’s obesity and type 2 diabetes contender’s positive phase III trial results; the strategic partnership between Sino Biological and BioGeometry; CSL’s sale of its China-based plasma collection operations…

Global Against the backdrop of a global push to make healthcare more accessible and affordable, ISPOR CEO and executive director Rob Abbott introduces the organisation’s 2030 strategy, focused on achieving health system sustainability around the world. The original version of this article was featured in the July/August 2024 edition of ISPOR’s Value…

Global AstraZeneca’s Anna Litsiou, Carolyn Hynes and Allison Guy, contributing to the September 2024 edition of DIA’s Global Forum magazine, discuss the importance of improving interactions between health technology assessment (HTA) bodies and regulatory authorities.   The need to optimize drug development and facilitate faster access for patients has focused discussions…

Switzerland Katharina Gasser of Roche Pharma Switzerland lays out her dedication to fostering innovation, strengthening team dynamics, and influencing the future of Switzerland’s healthcare landscape. Gasser emphasizes the need to combat complacency, advance digitalization, and promote diversity in leadership, noting that “complacency is a real threat—it stifles innovation, diminishes drive, and…

Switzerland Christof Kloepper delves into the Basel Area’s positioning as a leading hub for life sciences and biotech innovation. Kloepper emphasizes the region’s commitment to attracting global companies, nurturing startups, and building a strong ecosystem of talent, research, and infrastructure. He draws a comparison to Boston and highlights the Basel Area’s…

Switzerland Dr Stephan Mumenthaler, director of scienceindustries, highlights Switzerland’s strong position in the healthcare, life sciences, and pharmaceutical sectors and explores the nation’s commitment to innovation, sustainability, and maintaining global competitiveness.   Switzerland remains a premier destination for the healthcare, life sciences, and pharmaceutical industries, consistently ranking among the top countries…

Mexico Francisco Chavez from Thermo Fisher Scientific explains the company’s global mission to advance science and healthcare, with a particular focus on Latin America. Chavez highlights Thermo Fisher’s significant investment in R&D and its strategic approach to addressing regional healthcare challenges through public-private partnerships.   Our commitment is to create a…

UAE Pfizer has a new regional president for its vast Middle East, Russia and Africa (MERA) country grouping. Turkish national Elif Aral, a 29-year Pfizer veteran, will take over from Patrick van der Loo, who becomes Pfizer Germany’s country president.   The Context This is a challenging and diverse region, where…

Global Some of the key projections for the global use of medicines up to 2028, drawn from IQVIA’s report, The Global Use of Medicines 2024: Outlook to 2028. The report states that growth outlook has been raised by 2 percentage points despite lower expectations for COVID-19 vaccines and therapeutics. This increase in…

Global The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez shares some exclusive insights on where pharma has made significant strides on the important metric of ‘patient reach’ and the…